TransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Taylor Frigon Capital Management LLC

Taylor Frigon Capital Management LLC boosted its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 28.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,540 shares of the company's stock after buying an additional 6,922 shares during the period. TransMedics Group makes up approximately 1.3% of Taylor Frigon Capital Management LLC's investment portfolio, making the stock its 26th largest holding. Taylor Frigon Capital Management LLC owned 0.09% of TransMedics Group worth $2,122,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Campbell Newman Asset Management Inc. boosted its position in TransMedics Group by 1.4% in the first quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company's stock valued at $782,000 after buying an additional 166 shares during the last quarter. Arizona State Retirement System grew its stake in shares of TransMedics Group by 1.9% during the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock worth $603,000 after purchasing an additional 184 shares during the period. Valmark Advisers Inc. grew its stake in shares of TransMedics Group by 4.5% during the 1st quarter. Valmark Advisers Inc. now owns 7,213 shares of the company's stock worth $485,000 after purchasing an additional 309 shares during the period. Envestnet Portfolio Solutions Inc. grew its stake in shares of TransMedics Group by 7.2% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company's stock worth $294,000 after purchasing an additional 317 shares during the period. Finally, NBC Securities Inc. acquired a new stake in shares of TransMedics Group during the 1st quarter worth approximately $25,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Insider Buying and Selling at TransMedics Group

In other news, insider Anil P. Ranganath sold 686 shares of TransMedics Group stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider now owns 13,955 shares in the company, valued at $1,950,909. The trade was a 4.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David Weill sold 732 shares of TransMedics Group stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the transaction, the director now owns 12,134 shares in the company, valued at approximately $1,503,159.92. This represents a 5.69% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,418 shares of company stock worth $1,512,613. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Trading Up 1.1%

Shares of TMDX stock opened at $131.45 on Monday. The stock's fifty day moving average is $118.51 and its two-hundred day moving average is $86.42. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10. The firm has a market capitalization of $4.45 billion, a P/E ratio of 96.65 and a beta of 2.10. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. The company had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The firm's revenue for the quarter was up 48.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.35 EPS. Research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TMDX. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Finally, Oppenheimer lifted their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $127.33.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.